

**Regd. & Corp. Office:**  
1506, Chiranjiv Tower,  
43, Nehru Place,  
New Delhi - 110019 (INDIA)

**Tel.:** 011 - 47589500-51 (50 Lines),  
**E-mail:** info@medicamen.com  
**Web:** www.medicamen.com  
**CIN No.:** L74899DL1993PLC056594

**Ref: STEX/DEV Report/2023-24**

**Date- 30.05.2023**

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street  
Mumbai- 400001

**National Stock Exchange of India Ltd**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051

Scrip Code- 531146

Symbol- MEDICAMEQ

**Sub: Statement for Deviation(s) or Variation(s) under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended March 31, 2023**

Dear Sir/Madam,

Pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/ 162/2019 dated December 24, 2019; please find enclosed herewith Statement of deviation(s) or variation(s) of funds raised through preferential issue by the Company in the specified format, for the quarter ended March 31, 2023. The same has been reviewed by the Audit Committee of the Company on 29.05.2023.

This for your information and records

Thanking you,

Yours faithfully

For **Medicamen Biotech Limited**

**Parul Choudhary**  
**Company Secretary & Compliance Officer**  
**ACS- 44157**

Statement of Deviation / Variation in utilization of funds raised						
Name of listed entity						
Mode of Fund Raising	Preferential Issues					
Date of Raising Funds	12.09.2022					
Amount Raised	Rs. 35,30,82,000					
Report filed for Quarter ended	31.03.2023					
Monitoring Agency	applicable/ not applicable					
Monitoring Agency Name, if applicable						
Is there a Deviation / Variation in use of funds raised	Yes / No					
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	NA					
If Yes, Date of shareholder Approval	NA					
Explanation for the Deviation / Variation	NA					
Comments of the Audit Committee after review	There is no deviation/variation in the utilization of funds					
Comments of the auditors, if any	NA					
Objects for which funds have been raised and where there has been a deviation, in the following table	NA					
Original Object	Modified Object, if any	Original Allocation	Modified allocation ,if any	Funds Utilized	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
a. The proceeds of the preferential issue shall be utilized to meet funding requirement for creating it's own marketing network in ten Francophone countries i.e., Ivory Coast, Ghana, Senegal, Cameroon, Burkina Faso, Benin, Togo, Niger, Mauritania and Mali by using distributing network of Euro Pharma, Paris.	Not Applicable	Rs. 31,93,15,875	Not Applicable	Rs. 21,00,00,000	Not Applicable	-
b. MBL will market 100 branded products in each country of this						

